A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).

Manmeet Singh Ahluwalia; David M. Peereboom; Ahmad Ozair; Atulya Aman Khosla; Yasmeen Rauf; Lakshmi Nayak; Marci Ciolfi; Tyler Alban; Matthew Grabowski; Pat Rayman; Marcella Diaz; Justin Lathia; Eudocia Quant Lee; Patrick Y. Wen; David A. Reardon

doi:10.1200/JCO.2024.42.16_suppl.2072

A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).

Manmeet Singh Ahluwalia
, David M. Peereboom
, Ahmad Ozair
, Atulya Aman Khosla
, Yasmeen Rauf
, Lakshmi Nayak
, Marci Ciolfi
, Tyler Alban
, Matthew Grabowski
, Pat Rayman
, Marcella Diaz
, Justin Lathia
, Eudocia Quant Lee
, Patrick Y. Wen
, David A. Reardon

Baptist Health South Florida

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	2072
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	42
Issue number	16_suppl
DOIs	https://doi.org/10.1200/JCO.2024.42.16_suppl.2072
State	Published - 2024

ASJC Scopus Subject Areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2024.42.16_suppl.2072

Cite this

Ahluwalia, M. S., Peereboom, D. M., Ozair, A., Khosla, A. A., Rauf, Y., Nayak, L., Ciolfi, M., Alban, T., Grabowski, M., Rayman, P., Diaz, M., Lathia, J., Lee, E. Q., Wen, P. Y., & Reardon, D. A. (2024). A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL). Journal of Clinical Oncology, 42(16_suppl), 2072. https://doi.org/10.1200/JCO.2024.42.16_suppl.2072

Ahluwalia, MS, Peereboom, DM, Ozair, A, Khosla, AA, Rauf, Y, Nayak, L, Ciolfi, M, Alban, T, Grabowski, M, Rayman, P, Diaz, M, Lathia, J, Lee, EQ, Wen, PY & Reardon, DA 2024, 'A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).', Journal of Clinical Oncology, vol. 42, no. 16_suppl, pp. 2072. https://doi.org/10.1200/JCO.2024.42.16_suppl.2072

@article{4c9879b6484849f9a601ea5c87520495,

title = "A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).",

author = "Ahluwalia, \{Manmeet Singh\} and Peereboom, \{David M.\} and Ahmad Ozair and Khosla, \{Atulya Aman\} and Yasmeen Rauf and Lakshmi Nayak and Marci Ciolfi and Tyler Alban and Matthew Grabowski and Pat Rayman and Marcella Diaz and Justin Lathia and Lee, \{Eudocia Quant\} and Wen, \{Patrick Y.\} and Reardon, \{David A.\}",

note = "Publisher Copyright: {\textcopyright} 2024 by American Society of Clinical Oncology",

year = "2024",

doi = "10.1200/JCO.2024.42.16\_suppl.2072",

language = "English",

volume = "42",

pages = "2072",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

number = "16\_suppl",

}

TY - JOUR

T1 - A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).

AU - Ahluwalia, Manmeet Singh

AU - Peereboom, David M.

AU - Ozair, Ahmad

AU - Khosla, Atulya Aman

AU - Rauf, Yasmeen

AU - Nayak, Lakshmi

AU - Ciolfi, Marci

AU - Alban, Tyler

AU - Grabowski, Matthew

AU - Rayman, Pat

AU - Diaz, Marcella

AU - Lathia, Justin

AU - Lee, Eudocia Quant

AU - Wen, Patrick Y.

AU - Reardon, David A.

PY - 2024

Y1 - 2024

UR - https://www.scopus.com/pages/publications/105024219307

UR - https://www.scopus.com/pages/publications/105024219307#tab=citedBy

U2 - 10.1200/JCO.2024.42.16_suppl.2072

DO - 10.1200/JCO.2024.42.16_suppl.2072

M3 - Article

AN - SCOPUS:105024219307

SN - 0732-183X

VL - 42

SP - 2072

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16_suppl

ER -

A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this